Xenon Blocks Neuronal Injury Associated with Decompression.

Area of Science:

• Marine Biology
• Neuroscience
• Biochemistry

Background:

• Neurologic decompression sickness (DCS) affects 30% of patients even with hyperbaric oxygen (HBO) treatment.
• DCS involves ischemic processes and excitotoxicity, suggesting combined therapies could improve outcomes.

Purpose of the Study:

• To investigate the neuroprotective effects of xenon in an ex vivo model of neurologic DCS.
• To determine if xenon can mitigate cell injury associated with rapid decompression.

Main Methods:

• An ex vivo model of neurologic DCS was utilized.
• Lactate dehydrogenase (LDH) release was measured as a marker of cell injury.
• The effect of xenon administration post-decompression was assessed.

Main Results:

• Fast decompression significantly increased LDH release compared to slow decompression.
• Xenon administration post-decompression effectively blocked the increase in LDH release.
• These findings indicate xenon's protective effect against decompression-induced cell injury.

Conclusions:

• Xenon demonstrates neuroprotective properties in an ex vivo model of neurologic DCS.
• Xenon may serve as an effective adjunctive therapy to hyperbaric oxygen (HBO) for treating neurologic DCS.
• Further research into xenon's role in DCS treatment is warranted.